137 related articles for article (PubMed ID: 31515627)
41. Histone H3 mutations in pediatric brain tumors.
Liu X; McEachron TA; Schwartzentruber J; Wu G
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018689. PubMed ID: 24691963
[TBL] [Abstract][Full Text] [Related]
42. Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
Nazem A; Lavezo J; Abdullaev Z; Aldape K; Quezado M; Cimino PJ; Pratt DW; Jenkins RB; Ida CM
J Neuropathol Exp Neurol; 2023 Dec; 83(1):58-60. PubMed ID: 37878797
[No Abstract] [Full Text] [Related]
43. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Wood MD; Neff T; Nickerson JP; Sayama C; Raslan AM; Ambady P; Corless CL; Nazemi KJ
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):460-463. PubMed ID: 33296093
[No Abstract] [Full Text] [Related]
44. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
Chan AK; Mao Y; Ng HK
N Engl J Med; 2016 Dec; 375(22):2206-2208. PubMed ID: 27959765
[No Abstract] [Full Text] [Related]
45. [H3K27 positive diffuse midline glioma. Report of one case].
Araneda P; Sujima E; Paredes-Manzo P; Vallejo R; Valdivia F; Sinning M; Gallegos M; Fuller G
Rev Med Chil; 2019 Nov; 147(11):1487-1490. PubMed ID: 32186609
[No Abstract] [Full Text] [Related]
46. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
47. A rare presentation of a spinal diffuse midline glioma in a child: a case report.
Isfaoun Z; Laasri K; Jidal M; Cherradi N; Melhaoui A; Chat L; Haddad SE; Kababri ME; Khorassani ME; Kili A; Ansari NE; Hessissen L
Pan Afr Med J; 2023; 44():183. PubMed ID: 37484594
[TBL] [Abstract][Full Text] [Related]
48. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours.
Nguyen AT; Colin C; Nanni-Metellus I; Padovani L; Maurage CA; Varlet P; Miquel C; Uro-Coste E; Godfraind C; Lechapt-Zalcman E; Labrousse F; Gauchotte G; Silva K; Jouvet A; Figarella-Branger D;
Neuropathol Appl Neurobiol; 2015 Apr; 41(3):403-8. PubMed ID: 25389051
[No Abstract] [Full Text] [Related]
49. Malignant gliomas with H3F3A G34R mutation or MYCN amplification in pediatric patients with Li Fraumeni syndrome.
Schoof M; Kordes U; Volk AE; Al-Kershi S; Kresbach C; Schüller U
Acta Neuropathol; 2021 Sep; 142(3):591-593. PubMed ID: 34264394
[No Abstract] [Full Text] [Related]
50. Biopsying a spinal cord lesion: A diagnostic dilemma. Case report and review of literature.
Dormegny L; Chibbaro S; Ganau M; Santin M; Kremer L; Proust F
Neurochirurgie; 2018 Dec; 64(6):425-430. PubMed ID: 30243464
[TBL] [Abstract][Full Text] [Related]
51. Neoplastic Myelopathies.
Wu J; Ranjan S
Continuum (Minneap Minn); 2018 Apr; 24(2, Spinal Cord Disorders):474-496. PubMed ID: 29613896
[TBL] [Abstract][Full Text] [Related]
52. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
53. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
54. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
55. Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas.
Ellis JA; Canoll P; McCormick PC; Feldstein NA; Anderson RC; Angevine PD; Kaiser MG; McCormick PC; Bruce JN; Ogden AT
J Neurooncol; 2012 Jan; 106(2):235-42. PubMed ID: 21789698
[TBL] [Abstract][Full Text] [Related]
56. Cytogenetic studies of pediatric brain and spinal cord tumors.
Chadduck WM; Boop FA; Sawyer JR
Pediatr Neurosurg; 1991-1992; 17(2):57-65. PubMed ID: 1815730
[TBL] [Abstract][Full Text] [Related]
57. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
58. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
59. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
[TBL] [Abstract][Full Text] [Related]
60. Familial multiple cavernomatosis: description of a new mutation.
Simón Gozalbo A; Beneyto M; Rodríguez-Luna D; Vilar Ventura RM; Belenguer Benavides A; Geffner Sclarsky D
Neurologia; 2011 Apr; 26(3):184-6. PubMed ID: 21163227
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
